Cell · 2025 · 39 citations · 36 references
Life SciencesImmunologyMolecular BiologyInnate ImmunityMolecular ImmunologyRna ProcessingInnate Immune ReceptorsInnate Immune RecognitionInnate Immune Signaling PathwaysToll-like ReceptorsImmunostimulatory PathwaysNucleasesToll-like Receptor LigandsToll-like Receptor SignalingToll-like Receptor Signaling PathwaysToll-like Receptor-mediated Innate Immune Response
Recognition of exogenous RNA by Toll-like receptors (TLRs) is central to pathogen defense. Using two distinct binding pockets, TLR7 and TLR8 recognize RNA degradation products generated by endolysosomal nucleases. RNA modifications present in endogenous RNA prevent TLR activation; notably, pseudouridine-containing RNA lacks immunostimulatory activity. Indeed, this property has been critical to the successful implementation of mRNA technology for medical purposes. However, the molecular mechanism for this immune evasion has remained elusive. Here, we report that RNase T2 and PLD exonucleases do not adequately process pseudouridine-containing RNA to generate TLR-agonistic ligands. As a second safety mechanism, TLR8 neglects pseudouridine as a ligand for its first binding pocket and TLR7 neglects pseudouridine-containing RNA as a ligand for its second pocket. Interestingly, the medically used N1-methylpseudouridine also evades RNase T2, PLD3, and PLD4 processing but is able to directly activate TLR8. Taken together, our findings provide a molecular basis for self-avoidance by RNA-sensing TLRs.
36
A Toll-like receptor recognizes bacterial DNA
Hiroaki Hemmi, Osamu Takeuchi, Taro Kawai et al. · Nature · 2000 · 6.4K citations
Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8
Florian Heil, Hiroaki Hemmi, Hubertus Hochrein et al. · Science · 2004 · 3.9K citations
Katalin Karikó, Hiromi Muramatsu, Frank A. Welsh et al. · Molecular Therapy · 2008 · 1.9K citations · Full text
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz, Mustafa Diken, Heinrich Haas et al. · Nature · 2016 · 1.7K citations
Life Sciences, Immunology, Oncology +17